Sebastian Pistritto, chief marketing officer at ParcelShield Holdings, LLC, talks about how technology such as artificial intelligence helps to evaluate data to assist in medication delivery service decision-making, depending on the need of the pharmacy and its patients.
Technology such as artificial intelligence can analyze performance delivery data to to help medication delivery service decision-making, depending on the need of the pharmacy and its patients, explains Sebastian Pistritto, chief marketing officer at the ParcelShield Holdings, LLC.
Transcript
What technology advancements have been effective at medication delivery?
I would say 2 things: there's much more rich data today available in the market, and there's also technology that can help you to access that data. That data is really performance delivery data that is across the carriers so that you have the ability to understand historically, what level of delivery performance has been successful in delivering patient medication on time.
How can data analytics and artificial intelligence be utilized to optimize medication delivery performance?
There's a lot of data out in the market today. The way artificial intelligence plays a part in that [is] it helps to really decipher all that data. Imagine 20 years’ worth of delivery performance data, whether it's the post office, whether it's UPS or whether it's FedEx, and the multiple different delivery services across all the homes and all the zip codes and all the states that this medication has to be delivered. Artificial Intelligence provides the ability to decipher through all that data and help us to make better decisions. “Well, which delivery method is better for my pharmacy? What is the optimum day to deliver that medication? How successful has a particular service level been in the past? Which carrier should I select in order to make sure that I am successful in making that delivery directly to the patient?”
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
HS Treatment Goals: Better Quality of Life, Not Just Control
January 3rd 2025For part 3 of our discussion with Chris Sayed, MD, we tackle several important topics in the hidradenitis suppurative (HS) and inflammatory disease space: patient quality of life, medication and treatment goals, and the possibility of a cure.
Read More
Dr Yehuda Handelsman: DCRM Guidelines Are Shaping Integrated, Global CRM Care
January 3rd 2025In part 2 of our interview, Yehuda Handelsman, MD, discusses how cardiorenalmetabolic (CRM) disease management is advancing with the 2022 Diabetes, Cardiorenal, and Metabolic (DCRM) multispecialty practice recommendations and the updated DCRM 2.0 guidelines.
Read More
Stripped of Fucose, Powerful Monoclonal Antibody Shows Promising Results in MDS Dosing Study
January 2nd 2025Nicole Grieselhuber, MD, PhD, of The Ohio State University, discusses results from Part D of a dosing study involving patients with previously untreated higher-risk myelodysplastic syndrome (MDS) who were treated with a combination of SEA-CD70 and azacitidine.
Read More